Health Care·Pharmaceuticals·$277.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.40 | N/A | -2.78% |
management commentary, guidance changes, and full analysis available with Pro.
| -2.78% |
Tone: Cautiously Optimistic
Overall, management expressed a cautious outlook, acknowledging the competitive landscape while reaffirming their focus on strategic initiatives.
Management highlighted ongoing challenges in the market.
They emphasized their commitment to innovation despite current pressures.
The earnings report showed a slight miss on EPS, which contributed to a 2.57% decline in the stock price. Investors may be concerned about the company's ability to navigate market challenges. Without any guidance provided, uncertainty remains about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
OTIS WORLDWIDE CORP
Jan 31, 2022